BBOT ▼ -2.3% - BridgeBio Oncology Therapeutics, Inc. $BBOT - BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers BridgeBio Pharma announced new data for its BBO-8520 program and outlined a strategic focus on the drug's use in second-line and later non-small cell lung cancer, alongside combination approaches for other candidates targeting KRAS-mutant cancers. The 2.3% decline suggests investors may have found the data or strategic positioning underwhelming relative to prior expectations, though specific clinical or commercial details from the announcement would drive the market's exact interpretation. 08-SEP-2026 04:07 PM ET